课题基金 / 基金详情

Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicity

Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicity
SARS-CoV-2 引起的全身毒性中重要器官的代谢和表观遗传重编程
批准号:
10272660
负责人:
Vaithilingaraja Arumugaswami
金额:
$363.65万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-17 至 2024-08-31

项目摘要

项目成果

Vaithilingaraja Arumugaswami的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract SARS-CoV-2 primarily affects the respiratory system but extra-pulmonary manifestations in individuals with COVID-19 are commonly seen. All major organ systems have been reported to be affected by SARS-CoV-2 and complications arising from ensuing organ dysfunction significantly increase the mortality rate of COVID-19. Yet, despite the clinical importance of systemic involvement of SARS-CoV-2, little is known about the pathogenesis of extra-pulmonary complications of COVID-19. Here, we create a murine model of SARS-CoV-2 induced severe systemic toxicity and multi-organ involvement and investigate the role of metabolic and epigenetic reprogramming of vital organs in the pathogenesis of systemic toxicity of COVID-19. We demonstrate that following a robust anti-viral immune response, there is metabolic suppression of oxidative phosphorylation and the tri-carboxylic acid (TCA) cycle in multiple organs. The animals develop a profound phenotype within 7 days of SARS-CoV-2 infection with severe weight loss, morbidity and failure to thrive. Examination of multiple internal organ systems demonstrated neutrophilia, lymphopenia, splenic atrophy, with cardiomyocyte cell death, myocardial edema and extreme myofibrillar disarray observed in the heart and mirroring reported human clinical phenotypes in COVID-19. An organ wide metabolic reprogramming consistent with depression of oxidative phosphorylation leads to utilization of peripheral fat stores and gross accumulation of fat in the heart, kidney, liver and other vital organs. We perform metabolomic profiling of peripheral blood and identify a panel of TCA cycle metabolites that serve as biomarkers of depressed oxidative phosphorylation, several of these markers been noted in human clinical studies to be associated with adverse prognosis. Finally, we demonstrate that despite the absence of viral genomes in tissues, transcriptional changes persist and are associated with significant differentially methylated regions in vital organs across the host cell genomes. Considering these observations, we dissect the mechanistic basis of such metabolic reprogramming in SARs-CoV-2. We have created a multi-disciplinary team comprising, metabolomics experts, virologists, physiologists and geneticists to study metabolic fluxes and organ wide transcriptomics to study in the depth the role of metabolic and epigenetic reprogramming in causing SARS-CoV-2 induced severe systemic toxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infection
  • 批准号:
    10322026
  • 项目类别:
  • 资助金额:
    $50.47万
  • 财政年份:
    2021
  • 负责人:
    Vaithilingaraja Arumugaswami
  • 依托单位:
Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infection
  • 批准号:
    10540701
  • 项目类别:
  • 资助金额:
    $52.03万
  • 财政年份:
    2021
  • 负责人:
    Vaithilingaraja Arumugaswami
  • 依托单位:
Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicity
  • 批准号:
    10846284
  • 项目类别:
  • 资助金额:
    $237.87万
  • 财政年份:
    2021
  • 负责人:
    Vaithilingaraja Arumugaswami
  • 依托单位:
国内基金
海外基金
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
  • 批准号:
    JCZRLH202600625
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
  • 批准号:
    2026JJ50619
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    翁春艳
  • 依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介 导“肠-胰岛 ”轴血糖调控功能的降糖机制研 究
  • 批准号:
    Y24H280055
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    颜美秋
  • 依托单位: